Skip to main content
SpringerLink
Log in

Nivolumab not cost effective for head and neck cancer

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2017 US dollars

Reference

  • Tringale KR, et al. Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. Journal of the National Cancer Institute : 3 Nov 2017. Available from: URL: http://doi.org/10.1093/jnci/djx226

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nivolumab not cost effective for head and neck cancer. PharmacoEcon Outcomes News 792, 21 (2017). https://doi.org/10.1007/s40274-017-4544-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-4544-0

Search

Navigation